Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552846 | 0.91 | PLA2G7 (0.38) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL7558429 | 0.90 | BACE1 (0.37) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL7569515 | 0.89 | BACE1 (0.36) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL7554707 | 0.89 | BACE1 (0.36) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL13081701 | 0.84 | BACE1 (0.44) | BACE1ARPGR | |
| SCHEMBL13441641 | 0.83 | BACE1 (0.38) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL2969276 | 0.81 | BACE1 (0.42) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL2969275 | 0.81 | BACE1 (0.42) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL7541460 | 0.81 | BACE1 (0.50) | BACE1BACE2ARPGRPLA2G7 | |
| SCHEMBL7581282 | 0.80 | PLA2G7 (0.38) | BACE1BACE2ARPGRPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PHARMACOPEIA INC. (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | BACE1, PRSS1, TMPRSS11D | BACE1 1/4885BACE2 29/4885AR 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.